Sugi Predict

Sugi Predict / Compounds / SCHEMBL5482486

SCHEMBL5482486

SCHEMBL5482486

CC(=O)Nc1nc(CC(=O)Nc2ncc(NCCOC(C)=O)s2)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 2/20 0.44
▸ DDB1 Q16531 2/20 0.44
▸ CDK12 Q9NYV4 2/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ GAA P10253 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ LMNA P02545 2/20 0.41
▸ POLB P06746 2/20 0.40
▸ ESR2 Q92731 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ SENP8 Q96LD8 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ SENP6 Q9GZR1 1/20 0.40
▸ PDE5A O76074 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5480446 0.94 CCNK (0.43) CCNKDDB1CDK12SMN1; SMN2KMT2A
SCHEMBL5482981 0.88 CCNK (0.48) CCNKDDB1CDK12SMN1; SMN2KMT2A
SCHEMBL5487537 0.86 CCNK (0.46) CCNKDDB1CDK12SMN1; SMN2KMT2A
SCHEMBL5481496 0.80 KMT2A (0.43) CCNKDDB1CDK12SMN1; SMN2KMT2A
SCHEMBL5477768 0.79 CCNK (0.42) CCNKDDB1CDK12SMN1; SMN2KMT2A
SCHEMBL24101425 0.78 CCNK (0.66) CCNKDDB1CDK12SMN1; SMN2KMT2A
SCHEMBL5490457 0.77 SMN1; SMN2 (0.52) CCNKDDB1CDK12SMN1; SMN2KMT2A
SCHEMBL5484301 0.76 CDK2 (0.57) CCNKDDB1CDK12SMN1; SMN2KMT2A
SCHEMBL5480753 0.75 CCNE1 (0.48) SMN1; SMN2KMT2ANPC1RAB9AMEN1
SCHEMBL5484375 0.75 CCNE1 (0.51) CCNKDDB1CDK12SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1204649-B1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-10-17 — — EP disclosed
US-20050004120-A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents PHARMACIA ITALIS S.P.A. (IT) 2005-01-06 — — US disclosed
US-6784198-B1 2-(ARYLMETHYL-CARBONYLAMINO)-1,3-THIAZOLE DERIVATIVES; CDK/CYCLIN KINASE INHIBITORY ACTIVITY PHARMACIA ITALIA S.P.A. (IT) 2004-08-31 — — US disclosed
EP-1204649-A1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2002-05-15 — — EP disclosed
WO-2001014353-A1 ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA, S.P.A. (IT) 2001-03-01 — — WO disclosed
US-6114365-A Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2000-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004120-A1 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents CCAR2, BCL2, ROS1 CCNK 214/4885DDB1 784/4885CDK12 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.